Kaléo Licenses Auto-Injector Technology to Amgen

M&A · Partnership
โดย GlobeNewswire·Read original
Summary · why it matters

Kaléo has entered into a confidential license agreement with Amgen, granting Amgen rights to certain of Kaléo's patented auto-injector technology. Financial and other terms were not disclosed. The agreement highlights Kaléo's role in drug-device innovation and its leadership in patient-centric auto-injector solutions.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Amgen Inc
AMGN
▲ PositiveTechnologyrelevance

Amgen gains rights to Kaléo's patented auto-injector technology, enhancing its drug-device capabilities.

Off-coverage companies 1

KaléoPrivate▲ Positive
Capitalrelevance

Kaléo enters a license agreement with Amgen, though financial terms undisclosed, highlighting its innovation leadership.

© 2026 MarketDXNews